UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000030166
Receipt No. R000034415
Scientific Title Evaluation of postprandial salinity concentration in blood: a randomized, double-blind, placebo-controlled, crossover trial
Date of disclosure of the study information 2017/11/29
Last modified on 2018/04/24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of postprandial salinity concentration in blood: a randomized, double-blind, placebo-controlled, crossover trial
Acronym Evaluation of postprandial salinity concentration in blood
Scientific Title Evaluation of postprandial salinity concentration in blood: a randomized, double-blind, placebo-controlled, crossover trial
Scientific Title:Acronym Evaluation of postprandial salinity concentration in blood
Region
Japan

Condition
Condition Healthy Japanese adult people
Classification by specialty
Not applicable Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To verify the effects on postprandial salinity concentration in blood with the intake of the test food
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes Area under curve (AUC) of sodium concentration (Na) in blood between before meal and 120 minutes after meal

* Take blood samples before eating the prescribed diet and at 30, 60, 90, and 120 minutes after meal (total 5 times).
Key secondary outcomes 1-1. Sodium (Na) concentration in blood
1-2. Iron (Fe) concentration in blood
1-3. Potassium (K) concentration in blood
1-4. Chloride (Cl) concentration in blood
1-5. Inorganic phosphate (IP) concentration in blood
2. systolic blood pressure, diastolic blood pressure, and pulse rate

*1 Take blood samples before eating the prescribed diet and at 30, 60, 90, and 120 minutes after meal (total 5 times). For 1-1, the blood sodium concentration is evaluated before meal and at 30, 60, 90, and 120 minutes after meal. For 1-2 ~ 1-5, the area under curve (AUC) is evaluated between before meal and 120 minutes after meal.
*2 Physical examination is conducted before eating the prescribed diet and at 30, 60, 90, and 120 minutes after meal (total 5 times).

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification NO
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment No need to know

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 I. Salt excretion supplement
II. Placebo supplement
* The intervention sequence is I-II, and each food is single ingestion.
* Take 3 capsules before eating the prescribed diet (2 rice balls: the intake of sodium will be approximately 1750 mg).
* Eat the prescribed diet with a glass of water (280 ml).
*Washout period is for 1 week and more.
Interventions/Control_2 I. Placebo supplement
II. Salt excretion supplement
* The intervention sequence is I-II, and each food is single ingestion.
* Take 3 capsules before eating the prescribed diet (2 rice balls: the intake of sodium will be approximately 1750 mg).
* Eat the prescribed diet with a glass of water (280 ml).
* Washout period is for 1 week and more.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Healthy Japanese adult people

2. Subjects who are judged as eligible to participate in the study by the principal investigator

3. Select the participants as equal as possible based on sodium concentration in blood at screening
Key exclusion criteria 1. At least one previous medical history or under the treatment of malignant tumor, heart failure or myocardial infarction

2. Currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or other chronic diseases

3. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily

4. Currently taking medicines (include herbal medicines) and supplements

5. Subjects who are allergic to medicines and/or the test food related products

6. Subjects who are pregnant, breast-feeding, and planning to become pregnant

7. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial

8. Subjects who are judged as ineligible to participate in the study by the principal investigator
Target sample size 16

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kazuo YAMAMOTO
Organization ORTHOMEDICO Inc.
Division name CEO
Zip code
Address 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL 03-3818-0610
Email kazu@orthomedico.jp

Public contact
Name of contact person
1st name
Middle name
Last name Naoko SUZUKI
Organization ORTHOMEDICO Inc.
Division name R&D Department
Zip code
Address 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL 03-3818-0610
Homepage URL
Email nao@orthomedico.jp

Sponsor
Institute ORTHOMEDICO Inc.
Institute
Department

Funding Source
Organization TOY MEDICAL Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Medical Corporation Seishinkai, Takara Clinic
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

Other administrative information
Date of disclosure of the study information
2017 Year 11 Month 29 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 11 Month 21 Day
Date of IRB
Anticipated trial start date
2017 Year 11 Month 29 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 11 Month 29 Day
Last modified on
2018 Year 04 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034415

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.